within Pharmacolibrary.Drugs.ATC.N;

model N06DX04
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.6833333333333334e-06,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00318,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0012900000000000001,
    k12             = 0.213,
    k21             = 0.213
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06DX04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Lecanemab is a humanized monoclonal antibody that selectively binds to soluble aggregated amyloid-beta species (protofibrils). It is used for the treatment of Alzheimer's disease. Lecanemab was approved by the FDA in 2023 for patients with early Alzheimer's disease (mild cognitive impairment or mild dementia stage) due to Alzheimer's pathology.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported from phase 2 and phase 3 clinical studies of intravenous lecanemab in adult patients (older adults aged >50 years) with early Alzheimer's disease.</p><h4>References</h4><ol><li><p>Park, J, et al., &amp; Patel, K (2024). Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease. <i>The Annals of pharmacotherapy</i> 58(10) 1045–1053. DOI:<a href=\"https://doi.org/10.1177/10600280231218253\">10.1177/10600280231218253</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38095619/\">https://pubmed.ncbi.nlm.nih.gov/38095619</a></p></li><li><p>DeBattista, C, &amp; Schatzberg, AF (2024). The Black Book of Psychotropic Dosing and Monitoring. <i>Psychopharmacology bulletin</i> 54(3) 8–59. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38993656/\">https://pubmed.ncbi.nlm.nih.gov/38993656</a></p></li><li><p>Gustavsson, T, et al., &amp; Sehlin, D (2020). SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-β antibody in a mouse model of Alzheimer&#x27;s disease. <i>Translational neurodegeneration</i> 9(1) 37–None. DOI:<a href=\"https://doi.org/10.1186/s40035-020-00214-1\">10.1186/s40035-020-00214-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32951598/\">https://pubmed.ncbi.nlm.nih.gov/32951598</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06DX04;
